Products
PrSIBBORAN®
landiolol hydrochloride for injection
The information on this page is intended for Canadian healthcare professionals.
Indication
SIBBORAN (landiolol hydrochloride) is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial fibrillation and atrial flutter in perioperative, postoperative, or other acute circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
SIBBORAN is not intended for use in chronic settings.
Pediatrics (<18 years of age): Health Canada has not authorized an indication for pediatric use.
About SIBBORAN
Landiolol is a selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines adrenaline and noradrenaline on the heart, where beta-1-receptors are predominantly located.
SIBBORAN is supplied as a powder for solution. Each vial contains 300 mg landiolol hydrochloride, which is equivalent to 280 mg landiolol. SIBBORAN is intended for intravenous use in a monitored setting and should be administered by a qualified health care professional.
Serious warnings and precautions
During the administration of SIBBORAN (landiolol hydrochloride), patients should be carefully monitored, with particular attention to heart rate and blood pressure.
Prescribing information
For complete prescribing information, including contraindications, warnings and precautions, please consult the Product Monograph, available from Health Canada’s Drug Product Database.
Date of initial authorization: November 20, 2023 · Manufacturer: AOP Orphan Pharmaceuticals GmbH, Vienna, Austria
- Medical information
- medical [at] enoumenatx.com
- Adverse events & product quality complaints
- pv [at] enoumenatx.com
You may also report a suspected side effect to the Canada Vigilance Program (Health Canada).
Partnership
Commercialized in Canada by Enoumena Therapeutics, in partnership with AOP Health.
Partnering
Bring your innovation to Canadian patients.
Interested in licensing your product in Canada? We collaborate with companies seeking a dedicated Canadian partner to bring innovative therapies to patients.